BTL Aesthetics, the latest frontier in regenerative medicine, presented at SIME

We were with BTL Aesthetics, one of the most prestigious international companies dealing with regenerative aesthetic medicine, for the presentation to the press of all the 2023 novelties. We handled media and influencer relations during the company’s presence at SIES in Bologna and at the 44th SIME Congress of Aesthetic Medicine in Rome, organizing two press conferences, first in Milan and then in Rome. To explain the new patent, soon to arrive also in Italy, we organized interviews with Carolyn Jacob, MD Dermatologist and Aesthetic Surgeon from Chicago, and with BTL Italia CEO Fabio Gugliucci.

The focus is on the international launch of Emface, the first device that treats skin and facial muscles together using only facial muscle stimulation without needles or surgery.  Emface is the first device currently on the market that uses the simultaneous application of two different synchronized energies, the latest frontier in regenerative medicine: the synchronized Radio Frequency reshapes and smoothes the skin by heating the dermis and increasing levels of collagen and elastin fibers, and HIFES™ technology simultaneously restores and elevates facial tissue support by selectively contracting muscles and increasing the density and quality of muscle structure.

The news was picked up by more than 50 industry and women’s magazines. Vanity Fair “EMFACE, eliminates facial wrinkles with only stimulation of facial muscles”; Il Sole 24 Ore, L’Espresso and Dermakos talk about “Facial rejuvenation with tissue stimulation”; Sanihelp headlines “Emface the treatment without needles”; CipriaMagazine: “The first treatment that acts on facial muscles”; Agenparl: Emface the first treatment that eliminates wrinkles without surgery; Il Giornale “The treatment that reduces wrinkles by 37%”, to name a few.